Robert W. Baird analyst Eric Coldwell reiterated a Buy rating on Charles River Laboratories Intl on Wednesday, setting a price target of $461, which is approximately 12.88% above the present share price of $408.41.
Coldwell expects Charles River Laboratories Intl to post earnings per share (EPS) of $1.76 for the third quarter of 2021.
The current consensus among 10 TipRanks analysts is for a Strong Buy rating of shares in Charles River Labs (NYSE:CRL), with an average price target of $405.5.
The analysts price targets range from a high of $485 to a low of $355.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $914.61 million and a net profit of $137.55 million. The company's market cap is $20.58 billion.
According to TipRanks.com, Robert W. Baird analyst Eric Coldwell is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 13.7% and a 63.98% success rate.
Charles River Laboratories International, Inc. is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions. It operates through the following segments: Research Models & Services, Discovery (NASDAQ:DISCA) & Safety Assessment and Manufacturing Support. The Research Models & Services segment comprises of the production and sale of research models, and also offers services designed to support its client's use of research models in screening non-clinical drug candidates. The Discovery & Safety Assessment segment offers discovery and safety assessment services, both regulated and non-regulated, in which it include both in vivo and in vitro studies, supporting laboratory services, and strategic preclinical consulting and program management to support product development. The Manufacturing Support segment provides endotoxin and microbial detection, avian vaccine and biologics testing solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.